A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy-Reference-Cited by-同舟云学术

A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Published:2022-09 Issue:9 Volume:40 Page:1060-1069.e7
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Zhang Ziyang,Rohweder Peter J.^ORCID,Ongpipattanakul Chayanid,Basu Koli,Bohn Markus-Frederik,Dugan Eli J.,Steri Veronica,Hann Byron,Shokat Kevan M.,Craik Charles S.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. {∖it PHENIX}: a comprehensive Python-based system for macromolecular structure solution;Adams;Acta Crystallogr. D,2010

2. Acquired resistance to KRASG12C inhibition in cancer;Awad;N. Engl. J. Med.,2021

3. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody;Bargou;Science,2008

4. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity;Canon;Nature,2019

5. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens;Chang;J. Clin. Invest.,2017

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers;Advanced Science;2024-09-10

2. The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax;Hemato;2024-08-27

3. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?;Lung Cancer;2024-08

4. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23

5. Design, synthesis, and antitumor activity evaluation of BF3-o, m, p-phenylenediamine bridged with pyrimidine-indole BF3 adduction derivatives;Molecular Diversity;2024-07-19